title: Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy.
abstract: Quantitative Systems Pharmacology (QSP) is an emerging science with increasing application to pharmaceutical research and development paradigms. Through case study we provide an overview of the benefits and challenges of applying QSP approaches to inform program decisions in the early stages of drug discovery and development. Specifically, we describe the use of a type 2 diabetes systems model to inform a No-Go decision prior to lead development for a potential GLP-1/GIP dual agonist program, enabling prioritization of exploratory programs with higher probability of clinical success.
authors.affiliation: Pfizer Worldwide Research and Development, Cardiovascular and Metabolic Diseases Research Unit, 610 Main Street, Cambridge, MA 02139, USA.
authors.forename: Theodore R
authors.initials: TR
authors.lastname: Rieger
authors.affiliation: Pfizer Worldwide Research and Development, Cardiovascular and Metabolic Diseases Research Unit, 610 Main Street, Cambridge, MA 02139, USA. Electronic address: cynthia.j.musante@pfizer.com.
authors.forename: Cynthia J
authors.initials: CJ
authors.lastname: Musante
mesh_terms: D015331:Cohort Studies; D003198:Computer Simulation; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004359:Drug Therapy, Combination; D005749:Gastric Inhibitory Polypeptide / Q000819:agonists*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000069450:Liraglutide / Q000008:administration & dosage; D010601:Pharmacology, Clinical / Q000379:methods*
chemical_list: D007004:Hypoglycemic Agents; D005749:Gastric Inhibitory Polypeptide; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
keywords: Gastric inhibitory peptide; Glucagon-like peptide 1; Mathematical modeling; Quantitative systems pharmacology; Type 2 diabetes